MAM
Celebrate National Chai Day without the cleanup hassle
Mumbai: It’s been a while since those long weekends, and with the daily office routine, fatigue has started to settle in. This weekend, take a break and gather your friends for a chai party to reconnect. Picture this – friends gathered, sipping on chai, sharing stories, and engaging in conversations. It’s a moment to step away from the busy pace of life and connect with those who matter.
What better occasion than National Chai Day? From a Desi High Tea Party and chai-tasting to the classic ‘Chai pe Charcha,’ there are plenty of ways to unwind. However, cleaning up afterward can be challenging, as chai stains and residue on utensils often require extra effort to clean.
Influencer Mahita Vankayala shared, “Whether I am alone or with friends, chai is my go-to drink. Alas, cleaning chai utensils can be a real hassle, but ITC Nimeasy has made it a breeze. Its Enzyme Technology* and Lift Off Action^ swiftly remove even the toughest stains, making the post-chai session cleanup a stress-free experience.”
To start, rinse your stained mug or teapot with warm water to loosen any surface residue. Next, apply a small amount of ITC Nimeasy dish soap directly to the stains. Its Enzyme Technology* effectively removes tough stains through its Lift Off Action^. For stubborn marks, fill your mug or teapot with warm water and Nimeasy, allowing them to soak for easier stain removal. Finally, rinse thoroughly with warm water, and your mugs and teapot will be clean and ready for your next chai session.
^Based on lab study on food samples
*Based on lab study on food soil
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
